Medpace Holdings Inc
NASDAQ:MEDP

Watchlist Manager
Medpace Holdings Inc Logo
Medpace Holdings Inc
NASDAQ:MEDP
Watchlist
Price: 586.83 USD 2.77%
Market Cap: 16.5B USD

Medpace Holdings Inc
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Medpace Holdings Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Medpace Holdings Inc
NASDAQ:MEDP
Operating Income
$507m
CAGR 3-Years
25%
CAGR 5-Years
28%
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Operating Income
$8B
CAGR 3-Years
-5%
CAGR 5-Years
6%
CAGR 10-Years
13%
Danaher Corp
NYSE:DHR
Operating Income
$4.7B
CAGR 3-Years
-14%
CAGR 5-Years
6%
CAGR 10-Years
7%
Mettler-Toledo International Inc
NYSE:MTD
Operating Income
$1.1B
CAGR 3-Years
1%
CAGR 5-Years
8%
CAGR 10-Years
8%
Agilent Technologies Inc
NYSE:A
Operating Income
$1.5B
CAGR 3-Years
-3%
CAGR 5-Years
12%
CAGR 10-Years
11%
IQVIA Holdings Inc
NYSE:IQV
Operating Income
$2.3B
CAGR 3-Years
6%
CAGR 5-Years
27%
CAGR 10-Years
13%
No Stocks Found

Medpace Holdings Inc
Glance View

Medpace Holdings Inc., a name renowned in the clinical research sector, operates at the heart of the drug development process. Founded in 1992 by Dr. August Troendle, Medpace carved a niche for itself as a full-service clinical contract research organization (CRO). The essence of its operation lies in managing the complex journey of bringing new pharmaceuticals and medical devices from conception through to approval. Medpace partners with various biopharmaceutical companies to design, conduct, and oversee clinical trials, aligning with regulatory requirements to ensure these products are safe and effective. The company stands out by offering a comprehensive suite of services, including strategic consulting, project management, and the integration of cutting-edge technologies—a holistic approach that often distinguishes it from competitors. The engine driving Medpace’s profitability is its model of operational excellence fueled by its disciplined and integrated approach. The company generates revenue primarily from the contracts it secures with sponsors for conducting each phase of clinical trials. By closely collaborating with its clients, Medpace ensures tailored solutions that operate under specified timelines and budgets, enhancing client retention and attracting new business. What truly underlines Medpace’s financial success is its ability to deliver high-quality results, evidenced by robust data captured during trials and the attainment of key endpoints. This reputation for quality not only nurtures client trust but also consolidates Medpace's standing as a pivotal player in the CRO industry, securing a sustainable revenue stream and ongoing growth in a competitive landscape.

MEDP Intrinsic Value
380.79 USD
Overvaluation 35%
Intrinsic Value
Price

See Also

What is Medpace Holdings Inc's Operating Income?
Operating Income
507m USD

Based on the financial report for Sep 30, 2025, Medpace Holdings Inc's Operating Income amounts to 507m USD.

What is Medpace Holdings Inc's Operating Income growth rate?
Operating Income CAGR 5Y
28%

Over the last year, the Operating Income growth was 24%. The average annual Operating Income growth rates for Medpace Holdings Inc have been 25% over the past three years , 28% over the past five years .

Back to Top